Dillon & Associates’s Eli Lilly LLY Stock Holding History

Dillon & Associates’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.23M	Buy	8,951 +1,840	+26%	+$1.87M	1.13%	23
2025 Q4	$7.64M	Buy	7,111 +1,138	+19%	+$1.09M	0.99%	26
2025 Q3	$4.56M	Buy	5,973 +1,745	+41%	+$1.3M	0.59%	35
2025 Q2	$3.3M	Buy	4,228 +1,706	+68%	+$1.33M	0.45%	38
2025 Q1	$2.08M	Buy	2,522 +1,276	+102%	+$1.06M	0.31%	44
2024 Q4	$962K	Buy	1,246 +794	+176%	+$657K	0.13%	56
2024 Q3	$400K	Hold	452	–	–	0.06%	66
2024 Q2	$409K	Hold	452	–	–	0.06%	67
2024 Q1	$352K	Hold	452	–	–	0.06%	69
2023 Q4	$264K	Sell	452 -19	-4%	-$11.1K	0.05%	73
2023 Q3	$253K	Buy	471 +20	+4%	+$10.3K	0.05%	72
2023 Q2	$212K	Buy	+451	New	+$189K	0.04%	77

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dillon & Associates's LLY Position: Q1 2026 in Review

Dillon & Associates increased its Eli Lilly (LLY) stake by 26% in Q1 2026, buying an estimated $1.87M and bringing the position to 8,951 shares worth $8.23M. The position accounts for 1.13% of the portfolio, ranked #23.

Dillon & Associates first reported a position in LLY in Q2 2023 and has held it in 12 quarters since. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Dillon & Associates held 8,951 shares of Eli Lilly worth $8.23M as of Q1 2026.
Dillon & Associates bought 1,840 Eli Lilly shares in Q1 2026, an estimated $1.87M.
Eli Lilly made up 1.13% of Dillon & Associates's portfolio in Q1 2026, its #23 holding.
Dillon & Associates first reported a position in Eli Lilly in Q2 2023 and has held it in 12 quarters since.
4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.